$ALBO

Albireo Pharma Inc

  • NASDAQ
  • Health Technology
  • Pharmaceuticals: Other
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

PRICE

$22.26 ▲5.348%

Last Close

VOLUME

245,702

DAY RANGE

19.51 - 21.28

52 WEEK

17.81 - 37.86

Join Discuss about ALBO with like-minded investors

profile
@dros #droscrew
recently

+Initiations 3/28: $ALBO $ASND $BBAI $BEP $BTCS $DRCT $GBT $GMED $HTZ NUVA $OBSV $ONCR $RBLX $SPIR $TCB $TCN $U

42 Replies 7 👍 14 🔥

profile
@Cozzamara #decarolis
recently

https://www.organismocf.it/portal/web/portale-ocf/ricerca-nelle-sezioni-dell-albo?p_p_id=RicercaConsulete_INSTANCE_kVo1fAhvcv2j&p_p_lifecycle=1&p_p_state=normal&p_p_mode=view&_RicercaConsulete_INSTANCE_kVo1fAhvcv2j_javax.portlet.action=ricercaConsulente&p_auth=ePA8iwhz

102 Replies 12 👍 15 🔥

profile
@dros #droscrew
recently

largest put/call: $ALBO

104 Replies 9 👍 13 🔥

Key Metrics

Market Cap

409.12 M

Beta

0.77

Avg. Volume

282.72 K

Shares Outstanding

19.36 M

Yield

0%

Public Float

0

Next Earnings Date

2022-08-04

Next Dividend Date

Company Information

Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.

CEO: Gary Gemignani

Website:

HQ: 10 Post Office Square Boston, 02109 Massachusetts

Related News